<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452124</url>
  </required_header>
  <id_info>
    <org_study_id>IQOS-ATTIKON</org_study_id>
    <nct_id>NCT03452124</nct_id>
  </id_info>
  <brief_title>The Effects of I Quit Ordinary Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers</brief_title>
  <official_title>The Effects of I Quit Ordinary Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      I quit ordinary smoking (IQOS) is proposed as a bridge to smoking cessation. In this study
      the investigators will examine its effects on aortic elasticity, glycocalyx integrity, and
      exhaled carbon monoxide (CO) concentration, both acutely and after 1 month of use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two smokers groups matched for age and sex will be assessed:

        1. a group of 30 current smokers with no diagnosed cardiovascular disease as the control
           group for chronic phase

        2. a group of 30 current smokers with no diagnosed cardiovascular disease who will be using
           the I quit ordinary smoking (IQOS) for 1 month.

      In the acute phase all 60 smokers will undergo a &quot;sham&quot; smoking for 7 minutes. Afterwards all
      60 smokers will be randomized to smoke either a normal cigarette or IQOS and the after 60
      minute washout period these subjects will be crossed over to the altenate mode of smoking
      (IQOS or normal cigarette respectively).

      After the completion of the acute phase all 60 smokers will start the use of IQOS for one
      month.

      In the acute phase, measurements will be performed at baseline, after sham smoking and after
      smoking of the normal cigarette or IQOS. The chronic phase measurements will be performed 1
      month after use IQOS. Thirty current smokers of similar age and sex will serve as controls
      and will have measurements at baseline and 1 month after baseline assessment.

      In both phases the investigators will assess: a) the aortic pulse wave velocity (PWV) and
      augmentation index (AIx) by Arteriograph and Complior; b) the perfusion boundary region of
      the sublingual arterial microvessels using Sideview, Darkfield imaging (Microscan,
      Glycocheck); c) the exhaled carbon monoxide (CO) level (parts per million -ppm) as a smoking
      status marker; d) the vital signs; e) an electrocardiogram; and f) plasma levels of C-
      reactive protein (CRP), transforming growth factor-b (TGF-b), lipoprotein associated
      phospholipase A2 (LP- LPA2), tumor necrosis factor- α (TNF-α), interleukins 6 and 10 (IL-6
      and -10), procollagen propeptide type III (PIIINP), matrix metalloproteinase 2 and 9 (MMP-2
      and -9), and macrophage-colony stimulating factor (MCSF), malondialdehyde (MDA) and protein
      carbonyls (PCs).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute I quit ordinary smoking (IQOS) effects on pulse wave velocity</measure>
    <time_frame>7 minutes</time_frame>
    <description>Acute I quit ordinary smoking (IQOS) effects on pulse wave velocity (PWV, m/s) using tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute I quit ordinary smoking (IQOS) effects on endothelial glycocalyx thickness</measure>
    <time_frame>7 minutes</time_frame>
    <description>Acute I quit ordinary smoking (IQOS) effects on endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublinqual arterial microvessels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic I quit ordinary smoking (IQOS) effects on pulse wave velocity</measure>
    <time_frame>1 month</time_frame>
    <description>Chronic I quit ordinary smoking (IQOS) effects on pulse wave velocity (PWV, m/s) using tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic I quit ordinary smoking (IQOS) effects on endothelial glycocalyx thickness</measure>
    <time_frame>1 month</time_frame>
    <description>Chronic I quit ordinary smoking (IQOS) effects on endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublinqual arterial microvessels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>IQOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I quit ordinary smoking (IQOS) assistes cessation program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoker control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional cigarette smoking continuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I quit ordinary smoking (IQOS)</intervention_name>
    <description>I quit ordinary smoking (IQOS) assisted cessation program</description>
    <arm_group_label>IQOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette</intervention_name>
    <description>Conventional cigarette smoking continuation</description>
    <arm_group_label>Smoker control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active conventional cigarette smoker

        Exclusion Criteria:

          -  Health condition adversely affected by smoking

          -  History or presence of cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignatios Ikonomidis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attikon University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignatios Ikonomidis, MD</last_name>
    <phone>00302105832187</phone>
    <email>ignoik@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Pavlidis, MD</last_name>
    <phone>00302105832187</phone>
    <email>geo_pavlidis@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>&quot;Attikon&quot; University General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignatios Ikonomidis, MD</last_name>
      <phone>00302105832187</phone>
    </contact>
    <investigator>
      <last_name>Ignatios Ikonomidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Ignatios Ikonomidis</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

